Search filters

Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 169
  • 695
  • 449
  • 14
  • 31
  • 1
  • 4
  • 647

Found 697 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 2
Retinal vasculopathy with cerebral leukoencephalopathy (RVCL) is a very rare and fatal genetic condition that affects the smallest blood vessels, especially of the brain and eye. It causes damage in the brain and eye, and there is currently no treatment to reduce these areas of damage. Crizanlizumab has been shown …
99 years or below
All genders
See protocol section 2, Abstract
 GENETICS  MECHANISMS AND CLINICAL PHENOTYPES OF ARRHYTHMOGENIC CARDIOMYOPATHY
1 years - 99 years
All genders
Phase 4
The well-established, consistent and precise phenotyping developed in the previous ARVC Registry (and published as the Modified Task Force Criteria), with a comprehensive primary genotyping approach, search for genetic modifiers, and biomarker analysis will fulfill the long-term goals of this proposal to identify the genetic basis of all forms of …
 Generation Study
99 years or below
All genders
Phase 2
The Generation study is a clinical research study for individuals ages 60 to 75 with an increased genetic risk of developing clinical symptoms of Alzheimer’s disease. The study is enrolling persons who have two copies of the APOE4 gene An employee of the investigative site or an immediate family member …
 KCP-330-020
18 years - 99 years
All genders
Phase 2
The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each …
 A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF NIRAPARIB AND TUMOR-TREATING FIELDS IN RECURRENT GLIOBLASTOMA
22 years - 99 years
All genders
Phase 2
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is near uniformly fatal. Only three treatments have been approved by the US FDA for GBM in the past 2 decades: temozolomide, bevacizumab, and, most recently, tumor-treating fields (TTFields). TTFields represents a novel anti-cancer modality that creates …
121 - 130 of 697